Boston Scientific Corporation
BSX
株式のランク
#409
この企業概要は英語でのみ提供されています。
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
株価
$41.88
最終同期: 2026-10-30
時価総額
$60.69B
変化（1日）
-1.89%
変化（1年）
-58.42%
国
US
株式データ: Financial Modeling Prep·更新日: ·投資助言ではありません·計算方法
取引 Boston Scientific Corporation (BSX)
カテゴリー
Healthcare
Boston Scientific Corporation（BSX）の利益
Sep 2026 時点の利益 TTM: $3.66B
Boston Scientific Corporation の最新の財務報告によると、同社の現在の利益は $3.66B です。2025 年には $3.39B の利益を上げ、これは 2024 年の利益 $2.28B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Boston Scientific Corporation の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $3.66B | 7.98% |
| 2025 | $3.39B | 48.33% |
| 2024 | $2.28B | 14.96% |
| 2023 | $1.99B | 73.97% |
| 2022 | $1.14B | 6.04% |
| 2021 | $1.08B | -1,462.03% |
| 2020 | $-79.00M | -111.50% |
| 2019 | $687.00M | -51.69% |
| 2018 | $1.42B | 52.41% |
| 2017 | $933.00M | 427.12% |
| 2016 | $177.00M | -127.23% |
| 2015 | $-650.00M | 27.70% |
| 2014 | $-509.00M | 128.25% |
| 2013 | $-223.00M | -94.57% |
| 2012 | $-4.11B | -739.72% |
| 2011 | $642.00M | -160.40% |
| 2010 | $-1.06B | -18.73% |
| 2009 | $-1.31B | -35.60% |
| 2008 | $-2.03B | 256.94% |
| 2007 | $-569.00M | -83.90% |
| 2006 | $-3.54B | -496.75% |
| 2005 | $891.00M | -40.36% |
| 2004 | $1.49B | 132.35% |
| 2003 | $643.00M | 17.12% |
| 2002 | $549.00M | 1,147.73% |
| 2001 | $44.00M | -91.65% |
| 2000 | $527.00M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $6.56B | 79.53% |
US
|
|
| $6.60B | 80.66% |
IE
|
|
| $5.12B | 39.97% |
US
|
|
| $3.23B | -11.70% |
DE
|
|
| $1.42B | -61.21% |
US
|
Boston Scientific Corporationの純利益に関する質問
Boston Scientific Corporationの純利益はどのくらいですか？
2026年9月時点で、Boston Scientific Corporationの直近12か月の純利益は$3.66Bです。
Boston Scientific Corporationの2025年の純利益はどのくらいでしたか？
2025年のBoston Scientific Corporationの純利益は$3.39Bで、2024年（$2.28B）を48.33%上回りました。
Boston Scientific Corporationの純利益は2020年以降どのように推移していますか？
2020年から2025年までのBoston Scientific Corporationの純利益は、2025年（$3.39B）が最も高く、2020年（$-79.00M）が最も低くなっています。
Boston Scientific Corporationの純利益は類似企業と比べてどうですか？
Boston Scientific Corporationの純利益は$3.66Bで、上に挙げた類似企業5社のうち2社を上回っています。これらの企業の中で最も高いのはMedtronic plcで、$6.60Bです。